ArticleThe Lancet. Haematology2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Preetesh Jain et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
44 papers cite it
this papertrialcites it